key: cord-0697748-00nmnugg
authors: Rowley, Anne H
title: Diagnosing SARS-CoV-2 Related Multisystem Inflammatory Syndrome in Children (MIS-C): Focus on the Gastrointestinal Tract and the Myocardium
date: 2020-07-27
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1080
sha: ecbec2cd94c1e0e684ab6bfbc69f5b37818b8e44
doc_id: 697748
cord_uid: 00nmnugg

nan

A c c e p t e d M a n u s c r i p t

In this issue of CID, investigators from Spain describe their experience with Multisystem Inflammatory Syndrome in Children (MIS-C) during a 3-month period of high prevalence of SARS-CoV-2 infection in their country (Moraleda C et al, in press ). Similar to other reports from Europe and the U.S. [1] [2] [3] [4] , the vast majority of children with this disorder were in a relatively older age group (median 7.6 years with interquartile range 4.5-11.5 years) and had detectable IgG antibody to the virus. A minority had viral RNA identified by respiratory RT-PCR assay, and respiratory symptoms were uncommon. As reported previously, the classic features of the condition were fever with marked abdominal pain, with or without hypotension and myocardial dysfunction, raising the question as to whether the gastrointestinal tract is the primary site of viral infection in these children [5] . Stool RT-PCR assays were not performed, likely because of a lack of a clinically available, validated viral RT-PCR assay for stool. Whether MIS-C represents cytokine storm resulting from persistent infection of the gastrointestinal tract with SARS-CoV-2, or whether it represents a postinfectious albeit generally short-lived [4, 6, 7] sequelae of viral infection remains unknown.

Children with MIS-C can have findings that are observed in many other infectious and inflammatory illnesses of childhood, such as rash, conjunctival injection, and erythema of the oropharynx. Since these findings are non-specific, they are not particularly helpful in establishing the diagnosis. Because these features are present in patients with Kawasaki disease (KD), some clinicians view MIS-C and KD as the same clinical entity [8, 9] . But does it make sense to consider these to be the same disorder? The epidemiology of KD has remained consistent and unchanged worldwide for more than 50 years, with the vast majority of cases occurring in children <5 years of age. Asian children are at highest risk [10, 11] . Because there is presently no diagnostic test for KD, an essential component of the diagnosis is exclusion of illnesses with similar clinical features, as stated in the American Heart Association Guideline on Kawasaki Disease Diagnosis, Treatment, and Long-Term Management, "because the principal clinical findings that fulfill the diagnostic criteria are not specific" [12] . As noted by Moraleda and colleagues, it is now clear that MIS-C is related to SARS-

A c c e p t e d M a n u s c r i p t cannot be responsible for an illness that was well-established for decades prior to its emergence.

Moreover, the presence of virus-like intracytoplasmic inclusion bodies in KD tissues that are targeted by antibodies produced by patients following the disease strongly suggests a single presently unidentified viral agent or closely related group of viruses as the cause [13] [14] [15] , rather than multiple disparate etiologic agents. In marked contrast to KD, MIS-C has consistently been observed to target older children and adolescents [2, 16] , and the condition has not been observed in Asia [17, 18] . KD can result in potentially severe coronary artery complications, which require long-term monitoring, treatment, and follow-up [12] . It has been consistently reported that MIS-C can result in coronary artery dilation [2, 4] , which could potentially be due to interleukin 6 cytokine storm similar to that observed in systemic onset juvenile rheumatoid arthritis [19] . The very broad case definition for MIS-C is of concern when performing urgently needed research studies to understand the pathogenesis and long-term sequelae of this condition, because inclusion of children who have other conditions will skew results and obscure accurate conclusions.

The unique clinical features of MIS-C appear to be those related to the gastrointestinal tract and the A c c e p t e d M a n u s c r i p t myocardium. It is presently unknown whether myocardial dysfunction in MIS-C results from myocardial inflammation or myocardial edema related to cytokine storm, but the latter seems more likely, in view of the relatively rapid improvement in most children [4] . Similarly, the mechanism of gastrointestinal involvement is also unclear. When exploratory abdominal surgery has been performed in cases of MIS-C, the findings have been diffuse inflammation of the intestine and/or mesenteric lymphadenitis [4, 6] . Research studies of MIS-C should focus initially on older children and adolescents with the classic presentation of fever with severe abdominal pain, hypotension, and myocardial dysfunction, to avoid inclusion of children with KD and KD shock, acute COVID-19, other viral infections, and other conditions that fulfill the current MIS-C case definition. Because SARS-CoV-2 cases are increasing in the U.S., particularly in Southern and Western states, cases of MIS-C will unfortunately continue to be observed. Fortunately, MIS-C remains uncommon, and children appear to improve rapidly with intravenous gammaglobulin and/or corticosteroid therapy. Hopefully vaccine development will soon be successful, to enable prevention of COVID-19 respiratory disease, MIS-C and other complications of SARS-CoV-2 infection.

Multisystem Inflammatory Syndrome in Children in New York State

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

SARS-CoV-2 productively infects human gut enterocytes

Severe SARS-CoV-2 Infection in Children With Suspected Acute Abdomen: A Case Series From a Tertiary Hospital in Spain

Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Multi-institutional Study from New York City

Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis

Multi-Inflammatory Syndrome in Children related to SARS-CoV-2 in Spain

Nationwide epidemiologic survey of Kawasaki disease in Japan

Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association

A Protein Epitope Targeted by the Antibody Response to Kawasaki Disease

Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease

Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease

Hyperinflammatory shock in children during COVID-19 pandemic

Defining Association between COVID-19 and the Multisystem Inflammatory Syndrome in Children through the Pandemic

COVID-19 and Kawasaki Disease in Children

Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis

Coronary artery aneurysms are more severe in infants than in older children with Kawasaki disease

Kawasaki syndrome hospitalizations in the United States

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t